Enhabit, Inc. (NYSE:EHAB) Director Jeffrey Bolton Purchases 1000 Shares – MarketBeat


Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Enhabit, Inc. (NYSE:EHABGet Rating) Director Jeffrey Bolton bought 1,000 shares of Enhabit stock in a transaction on Friday, November 18th. The stock was purchased at an average price of $12.69 per share, for a total transaction of $12,690.00. Following the completion of the acquisition, the director now owns 15,597 shares in the company, valued at approximately $197,925.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Jeffrey Bolton also recently made the following trade(s):

  • On Wednesday, November 9th, Jeffrey Bolton purchased 2,000 shares of Enhabit stock. The shares were purchased at an average price of $12.75 per share, with a total value of $25,500.00.

Enhabit Trading Up 3.3 %

EHAB stock traded up $0.42 during midday trading on Tuesday, reaching $13.24. 728,248 shares of the company’s stock traded hands, compared to its average volume of 914,115. Enhabit, Inc. has a fifty-two week low of $11.65 and a fifty-two week high of $25.25. The stock’s 50-day simple moving average is $13.59. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.63.

Wall Street Analyst Weigh In

Several research firms have commented on EHAB. Oppenheimer initiated coverage on shares of Enhabit in a research note on Thursday, October 13th. They issued a “market perform” rating for the company. Credit Suisse Group dropped their price objective on shares of Enhabit from $19.00 to $15.00 and set a “neutral” rating for the company in a research note on Friday, November 4th. Jefferies Financial Group began coverage on shares of Enhabit in a report on Tuesday, August 30th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Citigroup began coverage on shares of Enhabit in a report on Thursday, August 18th. They issued a “neutral” rating and a $17.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $17.00.

Institutional Investors Weigh In On Enhabit

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Enhabit in the third quarter valued at approximately $97,492,000. Vanguard Group Inc. purchased a new stake in Enhabit during the 3rd quarter worth $77,886,000. State Street Corp purchased a new stake in Enhabit during the 3rd quarter worth $22,827,000. Systematic Financial Management LP acquired a new position in Enhabit in the 3rd quarter worth $20,566,000. Finally, Dimensional Fund Advisors LP purchased a new position in Enhabit in the 3rd quarter valued at about $9,662,000. 28.68% of the stock is currently owned by hedge funds and other institutional investors.

About Enhabit

(Get Rating)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

Further Reading

Insider Buying and Selling by Quarter for Enhabit (NYSE:EHAB)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Enhabit, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Enhabit wasn’t on the list.
While Enhabit currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
[email protected]
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

source


Leave a Reply

Your email address will not be published.